SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC

被引：3
|
作者：
Maguire, J.
McMenemin, R.
O'Rourke, N.
Peedell, C.
Snee, M.
Mcnee, S.
Kelly, V.
机构：
[1] Clatterbridge Ctr Oncol, Bebington, England
[2] Freeman Rd Hosp, Northern Ctr Canc Care, Dept Clin Oncol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[4] James Cook Univ Hosp, Middlesbrough, Cleveland, England
[5] St James Inst Oncol, Leeds, W Yorkshire, England
[6] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7039
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. outcome and patterns of failure
    Zimmermann, FB
    Schuhmacher, C
    Lersch, C
    Bernhardt, B
    Pickel, P
    Siewert, JR
    Molls, M
    Jeremic, B
    HEPATO-GASTROENTEROLOGY, 2004, 51 (60) : 1842 - 1846
  • [32] Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
    Cortiula, F.
    Hendriks, L.
    Wijsman, R.
    Houben, R.
    Steens, M.
    Debakker, S.
    Reverberi, C.
    Sijtsema, N. M.
    Niezink, A.
    Urban, S.
    Michelotti, A.
    Dursun, S.
    Bootsma, G.
    Hattu, D.
    Canters, R.
    Moretti, E.
    Taasti, V. T.
    De Ruysscher, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S748 - S749
  • [33] An audit comparing two different cisplatin schedules and subsequent nephrotoxicity for two different schedules used in concurrent chemoradiation: Sequential Or Concurrent Chemotherapy And Radiotherapy (SOCCAR) regime for inoperable non-small cell lung cancer
    Wakeham, K.
    Jones, R.
    Brisbane, I.
    Roxburgh, P.
    MacPhee, J.
    Hicks, J.
    LUNG CANCER, 2014, 83 : S7 - S7
  • [34] Concurrent chemotherapy and radiotherapy in NSCLC: Northampton experience
    Eldeeb, H.
    Lewis, A.
    LUNG CANCER, 2010, 67 : S30 - S30
  • [35] Paclitaxel (Taxol®) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC
    Isokangas, OP
    Joensuu, H
    Halme, M
    Jekunen, A
    Mattson, K
    LUNG CANCER, 1998, 20 (02) : 127 - 133
  • [36] Accelerated hypofractionated radiotherapy in inoperable lung cancer using Tomotherapy: the lausanne experience
    Bouchaab, H.
    Peters, S.
    Ris, H. B.
    Tsoutsou, P.
    Pachoud, M.
    Mirimanoff, R. O.
    Ozsahin, M.
    Matzinger, O.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 728 - 728
  • [37] Triplet induction chemotherapy followed by radiotherapy in inoperable stage III non small cell lung cancer (NSCLC).: A phase II report
    Schallier, D
    Neyns, B
    Vermeij, J
    Fontaine, C
    De Mey, J
    Meysman, M
    De Gréve, J
    LUNG CANCER, 2005, 49 : S268 - S268
  • [38] SURVIVAL IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING CONCURRENT CHEMOTHERAPY WITH HYPOFRACTIONATED RADIOTHERAPY: EXPERIENCE AT THE NORTHERN CENTRE FOR CANCER CARE (NCCC), UK
    Webb, Gregory
    Mcmenemin, Rhona
    Mcdonald, Fiona
    Mazdai, Goudarz
    Atherton, Philip
    Mulvenna, Paula
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1551 - S1552
  • [39] Cisplatin with concurrent accelerated hyperfractionation radiotherapy followed by consolidation chemotherapy with navelbine and cisplatin. A phase II trial for patients with inoperable stage IIINSCLC
    Gaafar, R
    Abdelbaki, H
    Safwat, A
    Mohamed, A
    Hamza, R
    Khaled, H
    El Hosseiny, H
    El Hosseiny, S
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 229 - 235
  • [40] First results of long term outcome in patients with inoperable or irresectable non-small cell lung cancer (NSCLC) treated with high-dose accelerated radiotherapy with or without concurrent or sequential chemotherapy
    Uitterhoeve, A.
    Koning, C.
    Koolen, M.
    Van Os, R.
    Koedooder, C.
    Van der Kar, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 329 - 329
12345